Blog

Welcome to the XerisDD Blog!

Upcoming Catalysts (Xeris)

Since many people ask about upcoming catalysts, I’ve decided to put together a few things that are on the horizon. A lot of the information can be found in the ER transcripts, but I know there are a lot of lazy investors who will never read an ER transcript so I’ll do my best to…

September 2021 Corporate Presentation Preview

These slides were part of the H.C. Wainwright 23rd Annual Global Investment Conference presentation which appear to be pages from the upcoming September 2021 Corporate Presentation.

$XERS – Ideal time to jump in

Source: r/pennystocks • Posted by u/ValterUdarnik • Original Post May you all be greeted fellow pennystockerians, today I want to remind you about XERIS, a commercial-stage pharma company which specializes in ready-to-use, liquid-stable injectables. I will present you some general information first to grasp the potential and after that the financial situation. Feel free to skip the parts…

Xeris enters into $71M Olguo commercialization agreement with Tetris Pharma

Xeris Pharmaceuticals Enters Into an Exclusive License and Supply Agreement with Tetris Pharma Limited to Commercialize Ogluo® in Europe Up to $71 million in time- and milestone-based payments, plus royalties on sales Agreement covers 32 countries First launch expected in Q4 2021 in UKJuly 19, 2021 08:00 AM Eastern Daylight Time CHICAGO–(BUSINESS WIRE)–Xeris Pharmaceuticals, Inc. (Nasdaq:…

Highlights from Xeris/Strongbridge S-4 (part 1)

Source: S-4 Xeris management believes Xeris can expand product offers: *[page 58]* “Xeris management identified that expanding Xeris’ product offerings to include a broader product portfolio would be a way to better position Xeris to execute on its economic value strategies.” Other companies were interested in Strongbride: *[page 59]*  “From September 2020 through the first…

XERS – Bull Case Shows 217% Upside while Bear Case Shows 42% Upside

The tl;dr is that a bull case evaluation for XERS shows an upside of 217% with PT $14.21 and a bear case evaluation shows an upside of 42% with PT $6.38. Note that this does not factor in the possibility of a short squeeze which could increase the price past its fundamental value. Given the…

An Undeserved Valuation: Xeris Pharmaceuticals

Source: Fortune Team | Jan 23 | Updated: Jan 24 | Blatantly undervalued and under-followed, Xeris has the potential to shine significantly in 2021, ascending as a true Fortune Alert( alerted initially in $2s). Take a look at our thoughts in a nutshell: Overview Xeris is a specialty pharmaceutical company that offers bold, innovative formulation technologies:…